Chimeric Antigen Receptor T Cell Therapy for Non-Hodgkin lymphoma

Non-Hodgkin lymphoma (NHL) is the most common hematologicmalignancy. Worldwide, approximately 200 000 people die of NHL everyyear. Recent advances in immunotherapeutic approaches for cancer haveresulted in the development of very effective immunotherapies includingengineered T cells expressing Chimeric Antigen Receptor (CAR) designedto bypass cancer immune evasion. US Food and Drug Administration(FDA) recently approved axicabtagene ciloleucel (Yescarta) andtisagenlecleucel (Kymriah) both CD19 CAR T cell therapies for thetreatment of relapsed refractory diffuse large B cell lymphoma (DLBCL),most common NHL. Approval of these two CAR T cell therapies is thefirst sign of a big wave that will dramatically change the way we treatcancer in general. Here I review the advances and challenges of CAR Tcell therapy for NHL.

Keywords:

Chimeric antigen receptor T cell therapy , Non-Hodgkin lymphoma